What it is: D3/K2 Liquid is a vegetarian, soy-free, orange-flavored liquid formula developed by DaVinci Labs, delivering 5,000 IU of Vitamin D3 (as cholecalciferol) and 500 mcg of Vitamin K2 (as MenaQ7® Menaquinone-7) per 1 ml serving in a sunflower oil base stabilized with mixed tocopherols and rosmarinic acid. The formula features MenaQ7® — a clinically tested, soy-free, patented MK-7 ingredient developed by Nattopharma ASA of Norway (U.S. Patent #8,354,129; Canada Patent #2,347,387) — representing one of the most extensively researched vitamin K2 forms available. The liquid delivery format provides an effective alternative to capsules for clients with swallowing difficulties, pediatric populations requiring flexible dosing, or those preferring liquid supplementation, while the sunflower oil base ensures optimal fat-soluble vitamin absorption with each serving.
How it works: D3/K2 Liquid supports bone health, calcium utilization, cardiovascular protection, and immune function through the well-characterized synergistic mechanisms of cholecalciferol and Menaquinone-7. Vitamin D3 (as cholecalciferol) — the preferred physiologically active dietary form of vitamin D — undergoes hepatic and renal hydroxylation to calcitriol, which binds to the nuclear vitamin D receptor (VDR) to upregulate intestinal calcium transport proteins, significantly enhancing dietary calcium absorption and systemic calcium availability for skeletal mineralization and neuromuscular function. Vitamin D3 additionally supports vascular function, healthy blood pressure within normal ranges, and immune cell regulation through VDR-mediated gene expression in immune tissue. MenaQ7® Vitamin K2 (as Menaquinone-7), standardized through Nattopharma's clinically validated manufacturing process, serves as the essential enzyme cofactor for gamma-carboxylation of osteocalcin — directing calcium into hydroxyapatite bone matrix — and matrix Gla-protein (MGP), the primary vascular calcification inhibitor that redirects calcium away from arterial walls and soft tissue. Together, D3 and MenaQ7® K2 address calcium metabolism comprehensively: D3 increases calcium availability, while K2 ensures that calcium is directed appropriately into bone rather than accumulating in vasculature — a clinically critical partnership that provides both bone-building and cardiovascular protection within a single formula.
When to use it: D3/K2 Liquid is appropriate for practitioner-directed use in adult and pediatric clients requiring fat-soluble vitamin D3 and K2 support for bone health, calcium utilization, cardiovascular protection, and immune function in a convenient liquid format. It is particularly well-suited for clients who cannot or prefer not to swallow capsules, those requiring flexible dose titration, clients with fat malabsorption who may benefit from the pre-dissolved lipid matrix delivery of the sunflower oil base, and those with vitamin D insufficiency requiring a maintenance 5,000 IU daily dose. One ml daily, well shaken before use, provides the full D3/K2 serving. This formula is contraindicated in clients taking anticoagulant or antiplatelet medications including Warfarin/Coumadin, and periodic serum 25(OH)D monitoring is recommended for individuals supplementing above 2,000 IU daily.
Serving Size: 1 ml
Servings Per Container: 30
Suggested Use: As a dietary supplement, take 1 ml daily, or as directed by your healthcare practitioner. Shake well before each use.
| Amount Per Serving | % Daily Value | |
| Vitamin D3 (as Cholecalciferol) | 125 mcg (5,000 IU) | 625% |
| Vitamin K2 (as Menaquinone-7 MenaQ7®) | 500 mcg | * |
* Daily Value not established.
Other Ingredients: Sunflower oil, natural orange flavor, mixed tocopherols, rosmarinic acid.
Caution: Do not take this product if taking anticoagulant/antiplatelet drugs such as Warfarin (Coumadin). If pregnant or nursing, consult your healthcare practitioner before taking this product. Individuals taking more than 50 mcg (2,000 IU) of Vitamin D per day should have their vitamin D levels monitored. Keep out of reach of children. Store in a cool, dry place. Shake well before each use.
✓ Vegetarian ✓ Gluten Free ✓ Soy Free
Key Ingredients
Vitamin D3 (as Cholecalciferol) — 125 mcg (5,000 IU) Cholecalciferol is the preferred physiologically active dietary form of vitamin D, identical to the form synthesized endogenously in human skin upon UVB exposure and substantially more effective than ergocalciferol (D2) at raising and sustaining serum 25(OH)D concentrations. Following hepatic and renal hydroxylation to its active hormone form calcitriol, cholecalciferol binds to the nuclear vitamin D receptor (VDR) to upregulate intestinal calcium transport proteins — including TRPV6 and calbindin-D9k — dramatically enhancing active calcium absorption in the small intestine and providing the systemic calcium availability essential for osteoblast-mediated bone mineralization, neuromuscular function, and VDR-mediated regulation of innate and adaptive immune function. Delivered in a sunflower oil base at 5,000 IU per 1 ml serving, this formula provides optimal fat-soluble absorption conditions for cholecalciferol while delivering a clinically relevant maintenance dose for bone health, immune support, and cardiovascular wellness protocols.
Vitamin K2 (as MenaQ7® Menaquinone-7) — 500 mcg MenaQ7® is a patented, clinically tested Menaquinone-7 (MK-7) ingredient developed by Nattopharma ASA of Norway (U.S. Patent #8,354,129; Canada Patent #2,347,387), produced through a controlled fermentation process and specifically formulated to be soy-free — an important distinction from most conventional MK-7 ingredients derived from natto soy fermentation. As the longest-acting form of vitamin K2, MenaQ7® maintains sustained carboxylation enzyme cofactor activity in peripheral tissues throughout a once-daily dosing interval, activating osteocalcin to direct calcium into hydroxyapatite bone matrix and carboxylating matrix Gla-protein (MGP) to actively inhibit arterial and soft tissue calcification. The clinical validation of MenaQ7® in human bone and cardiovascular outcome trials — including the landmark MenaQ7® three-year randomized controlled trial demonstrating significant improvements in bone mineral density and arterial stiffness — establishes it as one of the most evidence-supported K2 ingredients available and the preferred choice for practitioner-grade D3/K2 formulations.
